Biotechnology
Medical
Biopharmaceutical
Puma Biotechnology
$39.469876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$39.46
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.43 (1.10%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell PBYI and other stocks, options, ETFs, and crypto commission-free!
About
Puma Biotechnology Inc Common Stock, also called Puma Biotechnology, is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. Read More The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
Employees
272
Headquarters
Los Angeles, California
Founded
2010
Market Cap
1.50B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
1.04M
High Today
$39.75
Low Today
$38.57
Open Price
$38.90
Volume
234.65K
52 Week High
$71.70
52 Week Low
$17.60
Collections
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
Health
Cancer Prevention
Technology
News
Yahoo FinanceMar 19
Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia
Puma Biotechnology, Inc. PBYI announced that the regulatory body in Australia has granted a marketing approval to its kinase inhibitor, Nerlynx (neratinib). The drug is approved as an extended adjuvant treatment of HER2-positive early stage breast cancer in adult patients, previously treated with Roche’s RHHBY Herceptin-based adjuvant therapy. Notably, Puma’s Australian licensing partner Specialised Therapeutics Asia (STA) has received the marketing authorization from Australia’s Therapeutic Goods Administ...
BusinessWireMar 18
Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Bre
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that its licensing partner Specialised Therapeutics Asia (STA) has received marketing authorization from Australia’s Therapeutic Goods Administration (TGA) to commercialize NERLYNX® (neratinib) in Australia for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab based therapy. STA has submitted regulatory applications to gain approval to int...
Markets InsiderMar 14
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 12, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 30,688 shares of Puma common stock to five new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma...
Price Paid on Robinhood
13% Lower
Right Now
52 Week Low
$17.60
Average Price Paid
$45.51
52 Week High
$71.70
Earnings
-$2.49
-$1.61
-$0.72
$0.16
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 8, After Hours